Generali Investments Management Co LLC Purchases 4,941 Shares of Gilead Sciences, Inc. $GILD

Generali Investments Management Co LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,496 shares of the biopharmaceutical company’s stock after buying an additional 4,941 shares during the period. Generali Investments Management Co LLC’s holdings in Gilead Sciences were worth $2,589,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC lifted its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC boosted its holdings in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $133.06 on Tuesday. The stock has a market cap of $165.20 billion, a price-to-earnings ratio of -49.84 and a beta of 0.32. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50-day simple moving average of $129.45 and a 200 day simple moving average of $136.34. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter last year, the firm posted $2.01 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. On average, research analysts forecast that Gilead Sciences, Inc. will post -0.5 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s payout ratio is presently -122.85%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares of the company’s stock, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 82,000 shares of company stock valued at $10,641,790 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on GILD. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Truist Financial decreased their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Finally, Royal Bank Of Canada increased their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.